Jonathan Smith, DO
MOHS-Micrographic Surgery · Fairfax, VANPI 1427378595
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Lilly USA, LLC at 39.3% of the total. Reporting peaked in 2024 at $149 and has fallen 87.2% since, to $19 in 2025. That places this record below the midpoint for mohs-micrographic surgery clinicians in VA, where the typical reported total is $1,276.
Across 11 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$88
- UCB, Inc.$39
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$31
- Kyowa Kirin, Inc.$24
- LEO Pharma Inc.$23
- Helsinn Therapeutics (U.S.), Inc.$20
What the payments were for
- Food & beverage$224100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 4 | $88 |
| UCB, Inc. | 2 | $39 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $24 |
| LEO Pharma Inc. | 1 | $23 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $20 |
How this compares
$224 in reported general payments places this provider in the 20th percentile of 36 mohs-micrographic surgery providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 15 | $847 |
| Doxycycline Hyclate | 77 | $553 |
| Gentamicin Sulfate | 14 | $424 |
| Triamcinolone Acetonide | 14 | $54 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Fairfax
- Jeffrey ScottFairfax$3K
- Brian JohnsonNorfolk$16K
- Sherry MaraghAshburn$12K
- Kristin BibeeCharlottesville$11K
- Kenneth NealArlington$9K
- James BotaNorfolk$9K
- Brian JohnsonNorfolk$5K
- Matthew WallaceRichmond$4K
- Soonyou KwonVienna$4K
- Amir BajoghliMc Lean$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.